Common Fungal Infections of the Feet in Patients with Diabetes Mellitus

Drugs and Aging

Volumn 21, Issue 2, 2004, Pages 101-112

  Tan, James S ^a,b,e   Joseph, Warren S ^c,d  

^a Infectious Diseases Section   (United States)

^b SUMMA HEALTH SYSTEM   (United States)

^c TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLYLAMINE DERIVATIVE; AMOROLFINE; ANTIDERMATOPHYTIC AGENT; ANTIFUNGAL AGENT; BENZYLAMINE DERIVATIVE; BIFONAZOLE; CARBAMAZEPINE; CICLOPIROX; CLOTRIMAZOLE; DIGOXIN; DOFETILIDE; DRUG VEHICLE; ECONAZOLE; FLUCONAZOLE; GRISEOFULVIN; HALOPROGIN; IMIDAZOLE DERIVATIVE; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; NYSTATIN; POLYENE ANTIBIOTIC AGENT; PYRIDONE DERIVATIVE; QUINIDINE; SULCONAZOLE; TERBINAFINE; TIOCONAZOLE; TOLNAFTATE; UNINDEXED DRUG; UREA DERIVATIVE;

CANDIDA; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; DERMATOMYCOSIS; DERMATOPHYTE; DIABETES MELLITUS; DIAGNOSTIC PROCEDURE; DISEASE CLASSIFICATION; DISEASE PREDISPOSITION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG PENETRATION; DRUG TOLERABILITY; EPIDEMIOLOGICAL DATA; ERADICATION THERAPY; FUNGUS ISOLATION; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC DISEASE; HUMAN; HYPERKERATOSIS; IMMUNE DEFICIENCY; INFECTION SENSITIVITY; LABORATORY DIAGNOSIS; LIVER DISEASE; LIVER TOXICITY; MICROBIOLOGICAL EXAMINATION; MOULD; MYCOSIS; ONYCHOMYCOSIS; PRIORITY JOURNAL; RASH; REVIEW; SKIN MANIFESTATION; TASTE DISORDER; TINEA PEDIS; TREATMENT OUTCOME; YEAST;

AGED; ANTIFUNGAL AGENTS; ARTHRODERMATACEAE; BIOLOGICAL AVAILABILITY; DIABETES COMPLICATIONS; DIABETES MELLITUS; DRUG INTERACTIONS; HUMANS; HYPOGLYCEMIC AGENTS; METABOLIC CLEARANCE RATE; ONYCHOMYCOSIS; RANDOMIZED CONTROLLED TRIALS; TINEA PEDIS;

EID: 1442359936     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200421020-00003     Document Type: Review

References (65)

1. Tan JS, File Jr TM. Diagnosis and treatment of diabetic foot infections. Baillieres Best Pract Res Clin Rheumatol 1999; 13 (1): 149-61
2. Gupta AK, Konnikov N, MacDonald P, et al. Prevalence and epidemiology of toenail onychomycosis in diabetic subjects: a multicentre survey. Br J Dermatol 1998; 139 (4): 665-71
3. Farkas B, Paul C, Dobozy A, et al. Terbinafine (Lamisil) treatment of toenail onychomycosis in patients with insulin-dependent and non-insulin-dependent diabetes mellitus: a multicentre trial. Br J Dermatol 2002; 146 (2): 254-60
4. Romano C, Massai L, Asta F, et al. Prevalence of dermatophytic skin and nail infections in diabetic patients. Mycoses 2001; 44 (3-4): 83-6
5. Alteras I, Saryt E. Prevalence of pathogenic fungi in the toe-webs and toe-nails of diabetic patients. Mycopathologia 1979; 67 (3): 157-9
6. Lugo-Somolinos A, Sanchez JL. Prevalence of dermatophytosis in patients with diabetes. J Am Acad Dermatol 1992; 26: 408-10
7. Buxton PK, Milne LJR, Prescott RJ, et al. The prevalence of dermatophyte infection in well-controlled diabetics and the response to Trichophyton antigen. Br J Dermatol 1996; 134: 900-3
8. Gupta AK. Onychomycosis in the elderly. Drugs Aging 2000; 16 (6): 397-407
9. Robbins JM. Treatment of onychomycosis in the diabetic patient population. J Diabetes Complications 2003; 17: 98-104
10. Doyle JJ, Boyko WL, Ryu S, et al. Onychomycosis among diabetic patients: prevalence and impact of nonfungal foot infections. American Diabetes Association 60th Annual Scientific Session; 2000 Jun 9-13; San Antionio (TX). Arlington (VA): American Diabetes Association, 2000
11. Joseph WS. Fungal infections: handbook of lower extremity infections. 2nd ed. New York: Churchill Livingstone, 2002
12. Sabouraud R. A manual of regional topographical dermatology. New York: Rebman Company, 1912
13. Roberts DT, Taylor WD, Boyle J. Guidelines for treatment of onychomycosis. Br J Dermatol 2003; 148: 402-10
14. Elewski BE. Onychomycosis: pathogenesis, diagnosis, and management. Clin Microbiol Rev 1998; 11 (3): 415-29
15. Joish VN, Armstrong EP. Which antifungal agent for onychomycosis? A pharmacoeconomic analysis. Pharmacoeconomics 2001; 19: 983-1002
16. Ghannoum MA, Hajjeh RA, Scher H, et al. A large-scale North American study of funfal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. J Am Acad Dermatol 2000; 43: 641-8
17. Roberts DT. Prevalence of dermatophyte onychomycosis in the United Kingdom: results of an omnibus survey. Br J Dermatol 1992; 126 Suppl. 39: 23-7
18. Elewski B. Diagnostic techniques for confirming onychomycosis. J Am Acad Dermatol 1996; 35: S6-9
19. Evans EGV. Causative pathogens in onychomycosis and the possibility of treatment resistance: a review. J Am Acad Dermatol 1998; 38: S32-8
20. Kamna MF, Elewski B. A US epidemiologic survey of superficial fungal diseases. J Am Acad Dermatol 1996; 35: 539-42
21. Schlefman BS. Onychomycosis: a compendium of facts and a clinical experience. J Foot Ankle Surg 1999; 38: 290-302
22. Abu-Aliat SA, Howell SA, Moore MK, et al. The microbial flora of toenails in diabetes mellitus [abstract no. P-48]. Br J Dermatol 2003; 149 Suppl. 64: 38
23. Leyden JJ. Progression of interdigital infections from simplex to complex. J Am Acad Dermatol 1993; 28 (5 pt 1): S7-S11
24. Chiritescu MM, Chiritescu ME, Scher RK. Newer systemic antifungal drugs for the treatment of onychomycosis. Clin Podiatr Med Surg 1996; 13 (4): 741-58
25. Aly R, Berger T. Common superficial fungal infections in patients with AIDS. Clin Infect Dis 1996; 22 Suppl. 2: S128-32
26. Vander Straten MR, Hossain MA, Ghannoum MA. Cutaneous infections, dermatophytosis, onychomycosis, and tinea versicolor. Infect Dis Clin North Am 2003; 17: 87-112
27. Mehregan DR, Gee SL. The cost effectiveness of testing for onychomycosis versus empiric treatment of onychodystrophies with oral antifungal agents. Cutis 1999; 64 (6): 407-10
28. Lawry MA, Haneke E, Strobeck K, et al. Methods for diagnosing onychomycosis: a comprative study and review of the literature. Arch Dermatol 2000; 36: 1112-6
29. Elewski BE. Clinical pearl: diagnosis of onychomycosis. J Am Acad Dermatol 1995; 32: 500-1
30. Rippon JW. Medical mycology: the pathogenic fungi and the pathogenic actinomycetes. 3rd ed. Philadelphia: WB Saunders, 1988
31. Weitzman I, Summerbell RC. The dermatophytes. Clin Microbiol Rev 1995; 8 (2): 240-59
32. Clayton YM, Hay RJ, McGibbon DH, et al. Double-blind comparison of the efficacy or tioconazole and miconazole for the treatment of fungal infection of the skin and erythrasma. Clin Exp Dermatol 1982; 7: 543-51
33. Hanel H, Abrams B, Dittmar W, et al. A comparison of bifonazole and ciclopiroxolamine: in vitro animal and clinical studies. Mycoses 1988; 31: 632-40
34. Smith EB, Breneman DL, Griffith RF, et al. Double-blind comparison of naftifine cream and clotrimazole betamathasone deproipionate cream in the treatment of tinea pedis. Am J Dermatol 1992; 26: 125-7
35. Hay RJ, Clayton YM, Howell SA, et al. Management of combined bacterial and fungal foot infection in coal miners. Mycoses 1988; 31: 316319
36. Savin R. Successful treatment of chronic tinea pedis (moccasin type) with terbinafine (Lamisil). Clin Exp Dermatol 1989; 14: 116-9
37. Bell-Syer SE, Hart R, Crawford F, et al. A systematic review of oral treatments for fungal infections of the skin of the feet. J Dermatolog Treat 2001; 12: 69-74
38. Scher RK, Daniel CR. Podiatric approach to Onychomycosis. In: Joseph WS, editor. Nails: therapy, diagnosis and surgery. Philadelphia (PA): WB Saunders Co, 1990
39. Gupta AK. Pharmacoeconomic analysis of ciclopirox nail lacquer solution 8% and the new oral antifungal agents used to treat dermatophyte toe onychomycosis in the United States. J Am Acad Dermatol 2000; 43 (4 Suppl.): S81-95
40. Gabal MA. Study on the evaluation of the use of thiabendazole in the treatment and control of bovine dermatophytosis. Mycopathologia 1986; 93 (3): 163-8
41. Gupta AK, Joseph WS. Ciclopirox 8% nail lacquer in the treatment of onychomycosis of the toenails in the United States. J Am Podiatr Med Assoc 2000; 90 (10): 495-501
42. Seebacher C, Nietsch KH, Ulbricht HM. A multicenter, open-1label study of the efficacy and safety of ciclopirox nail lacquer solution 8% for the treatment of onychomycosis in patients with diabetes. Cutis 2001; 68 (2 Suppl.): 17-22
43. Friedman-Birnhaum R, Cohen A, Shemer A, et al. Treatment of onychomycosis: a randomized, double-blind comparison study with topical bifonazole-urea ointment alone and in combination with short-duration oral griseofulvin. Int J Dermatol 1997; 36: 67-9
44. Ishii M, Hamada T, Asai Y. Treatment of onychomycosis by ODT therapy with 20% urea ointment and 2% tolnaftate ointment. Dermatologica 1983; 167 (5): 273-9
45. Hammer KA, Carson CF, Riley TV. Antifungal activity of the components of melaleuca alternifolica (tea tree) oil. J Appl Microbiol 2003; 95: 853-60
46. Tom CM, Kane MP. Management of toenail onychomycosis. Am J Health Syst Pharm 1999; 56 (9): 865-71
47. Artis WM, Odle BM, Jones HE. Griseofulvin-resistant dermatophytosis correlates with in vitro resistance. Arch Dermatol 1981; 117 (1): 16-9
48. Jeremaisse HP. Treatment of nail infections with griseofulvin combined with abrasion. Trans St John Hosp Dermatol Soc 1960; 45: 92-3
49. Kucers A, Crowe SM, Grayson ML, et al., editors. The use of antibiotics: a clinical review of antibacterial, antifungal and antiviral drugs. 5th ed. Oxford: Butterworth-Heinemann, 1997
50. Editorial. Onychomycosis and terbinafine. Lancet 1990; 335: 636
51. Goodfield MJ, Rowell NR, Forster RA, et al. Treatment of dermatophyte infection of the finger- and toe-nails with terbinafine (SF 86-327, Lamisil), an orally active fungicidal agent. Br J Dermatol 1989; 121 (6): 753-7
52. Pierard GE, Arrese-Estrada J, Pierard-Franchimont C. Treatment of onychomycosis: traditional approaches. J Am Acad Dermatol 1993; 29 (1): S41-5
53. van der Schroeff JG, Cirkel PK, Crijns MB, et al. A randomized treatment duration-finding study of terbinafine in onychomycosis. Br J Dermatol 1992; 126 Suppl. 39: 36-9
54. Goodfield MJ. Short-duration therapy with terbinafine for dermatophyte onychomycosis: a multicentre trial. Br J Dermatol 1992; 126 Suppl. 39: 33-5
55. Crawford F, Young P, Godfrey C, et al. Oral treatments for toenail onychomycosis: a systematic review. Arch Dermatol 2002; 138 (6): 811-6
56. Alpsoy E, Yilmaz E, Basaran E. Intermittent therapy with terbinafine for dermatophyte toe-onychomycosis: a new approach. J Dermatol 1996; 23 (4): 259-62
57. Tosti A, Piraccini BM, Stinchi C, et al. Treatment of dermatophyte nail infections: an open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy. J Am Acad Dermatol 1996; 34 (4): 595-600
58. Gupta AK, Konnikov N, Lynde CW. Single-blind, randomized, prospective study on terbinafine and itraconazole for treatment of dermatophyte toenail onychomycosis in the elderly. J Am Acad Dermatol 2001; 44 (3): 479-84
59. Kavli G, Midelfart K, Moseng D, et al. Trichophyton rubrum infected toenails treated with ketoconazole and paaartial nail avulsion. Dermatologica 1984; 169: 191-3
60. Korting HC, Schafer-Korting M. Is tinea unguium still widely incurable? A review three decades after the introduction of griseofulvin. Arch Dermatol 1992; 128: 243-8
61. Albreski DA, Gross EG. The safety of itraconazole in the diabetic population. J Am Podiatr Med Assoc 1999; 89 (7): 339-45
62. Verspeelt J, Marynissen G, Gupta AK, et al. Safety of itraconazole in diabetic patients. Dermatology 1999; 198: 382-4
63. Ljunggren B, Bjellerup M. Systemic drug photosensitivity. Photodermatol 1986; 3: 26-35
64. Albengres E, Le Louet H, Tillement JP. Systemic antifungal agents. Drug interactions of clinical significance. Drug Saf 1998; 18: 83-97
65. Jalava KM, Olkkola KT, Neuvonen PJ. Itraconazole greatly increases plasma concentrations and effects of felodipine. Clin Pharmacol Ther 1997; 61: 410-5